Cyproterone acetate is used for topical treatment of diseases dependent on male hormones.
May 2018 in “Dermatologic Surgery”
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
August 2025 in “Pharmaceutics” A new method improves betulin delivery and shows promise in cancer treatment.
May 2026 in “Journal of Skin and Sexually Transmitted Diseases” Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
45 citations
,
January 2012 in “The Journal of Steroid Biochemistry and Molecular Biology” Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
22 citations
,
November 2005 in “BMC Cancer” Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
8 citations
,
May 2019 in “Journal of dermatological treatment” Vismodegib is effective for basal cell carcinoma but has severe side effects.
March 2007 in “Journal of Cell Science” K10 may not prevent tumors as previously thought and might increase benign tumor risk.
2 citations
,
January 2018 in “Elsevier eBooks” Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.
January 2021 in “Research Portal Denmark” Tofacitinib helped a man with alopecia totalis regrow all his hair.
July 2025 in “Journal of Investigative Dermatology”
1 citations
,
March 2011 in “Journal of Investigative Dermatology” Blocking RANK signaling might help treat metastatic melanoma, but more research is needed.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
68 citations
,
January 2013 in “BMC Pharmacology and Toxicology” Glibenclamide slows breast cancer cell growth by stopping cell division.
March 2026 in “Stem Cell Reviews and Reports”
14 citations
,
June 2021 in “Expert Opinion on Therapeutic Patents” New patents show progress in developing drugs targeting the Wnt pathway for diseases like cancer and hair loss.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
1 citations
,
October 2022 in “Дерматовенерология Косметология” EGFR inhibitors for lung cancer can cause severe skin issues.
14 citations
,
January 2022 in “Evidence-based Complementary and Alternative Medicine” Cryptotanshinone may help treat postmenopausal osteoporosis and protect kidneys.
February 2024 in “Journal of medicinal food” The research found a way to develop hair growth materials by targeting a specific signaling pathway.
September 2025 in “Cancer Innovation” Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.
April 2026 in “Phytotherapy Research” Licorice component glycyrrhizic acid may reduce skin side effects from cancer treatment.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
August 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Normal cells outcompete and remove mutant cells in the pancreas with the help of the EphA2 receptor.